Global Structural Heart Devices Market Size By Type (Annuloplasty Rings, Heart Valve Balloons), By Application (New Born (0-5 months), Infants (6 months to 12 months)), By Region, And Segment Forecast...

The Global Structural Heart Devices Market was valued at USD 10.5 billion in 2023 and is expected to surpass USD 19.2 billion by 2031, growing at a CAGR of 7.8% during the forecast period from 2023 to 2031. The market growth is driven by the rising prevalence of structural heart diseases, increasing demand for minimally invasive procedures, and advancements in medical device technologies. The growing aging population and lifestyle-related disorders contribute significantly to the demand for structural heart devices.

The increasing preference for transcatheter heart valve replacement (TAVR) procedures over open-heart surgeries, the expanding healthcare infrastructure in emerging economies, and favorable reimbursement policies further boost market expansion. Moreover, increasing investments in research and development (R&D) for next-generation heart valve devices are expected to create new growth opportunities.

Market Drivers:

1. Rising Prevalence of Structural Heart Diseases

The increasing burden of congenital and acquired structural heart diseases, such as aortic stenosis, mitral valve regurgitation, and atrial septal defects, is a key driver. A growing number of patients require interventions using structural heart devices.

2. Advancements in Minimally Invasive Procedures

The shift from traditional open-heart surgeries to minimally invasive procedures, including transcatheter aortic valve replacement (TAVR) and mitral valve repair, is driving market growth. These procedures offer reduced recovery time, lower risk of complications, and improved patient outcomes.

3. Aging Population and Associated Cardiovascular Diseases

Aging is a significant risk factor for structural heart diseases. With the global geriatric population rising, the demand for advanced heart valve replacement and repair technologies is increasing.

Market Restraints:

1. High Cost of Structural Heart Devices and Procedures

Structural heart devices, particularly transcatheter heart valves and occluders, are expensive, making them less accessible in developing countries with limited healthcare budgets.

2. Strict Regulatory Approval Process

Regulatory authorities such as the FDA and European Medicines Agency (EMA) impose stringent approval processes for new structural heart devices, which can delay market entry and limit the adoption of innovative technologies.

Market Opportunities:

1. Increasing Adoption of Transcatheter Procedures

Transcatheter techniques such as TAVR, transcatheter mitral valve repair (TMVR), and left atrial appendage closure (LAAC) are gaining traction due to their safety, efficacy, and reduced hospital stays.

2. Technological Innovations in Structural Heart Devices

Next-generation devices incorporating bioresorbable materials, artificial intelligence (AI)-based imaging, and robotic-assisted procedures are expected to drive market expansion.

3. Expanding Healthcare Infrastructure in Emerging Economies

Countries like China, India, and Brazil are investing in healthcare infrastructure, increasing accessibility to advanced cardiac procedures and boosting demand for structural heart devices.

Market by Device Type Insights:

The Heart Valve Devices segment dominated the market in 2023, accounting for the largest revenue share. Among these, transcatheter aortic valve replacement (TAVR) devices witnessed the highest demand due to their effectiveness in treating severe aortic stenosis in elderly and high-risk patients.

Other key device types include:

Occluders and Closure Devices – Used for atrial septal defect (ASD) and patent foramen ovale (PFO) closure.

Annuloplasty Rings – Widely used in mitral and tricuspid valve repair.

Mechanical and Bioprosthetic Heart Valves – Traditional solutions still relevant in certain patient populations.

Market by End-Use Insights:

In terms of end-use, the Hospitals and Cardiac Centers segment accounted for the highest market share in 2023. The demand for structural heart devices in these settings is driven by an increasing number of cardiovascular procedures and the availability of advanced cardiac care facilities.

Other significant end-use segments include:

Ambulatory Surgical Centers (ASCs) – Gaining popularity due to shorter hospital stays and lower procedural costs.

Specialty Clinics – Focused on outpatient care and post-surgical cardiac rehabilitation.

Market by Regional Insights:

North America dominated the Global Structural Heart Devices Market in 2023, with the United States leading the market due to high adoption rates of advanced structural heart procedures, well-established healthcare infrastructure, and favorable reimbursement policies.

Europe held the second-largest market share, driven by increasing awareness, government initiatives, and technological advancements in heart valve therapy.

Asia-Pacific is expected to witness the highest growth rate during the forecast period due to a rising geriatric population, increasing healthcare spending, and growing adoption of minimally invasive heart procedures in countries like China, India, and Japan.

Competitive Scenario:

Leading players in the Global Structural Heart Devices Market include:

Edwards Lifesciences Corporation

Medtronic plc

Abbott Laboratories

Boston Scientific Corporation

LivaNova PLC

CryoLife, Inc.

Braile Biomédica

JenaValve Technology, Inc.

Micro Interventional Devices, Inc.

Meril Life Sciences Pvt. Ltd.

These companies focus on strategic partnerships, new product launches, and acquisitions to strengthen their market positions. For example:

In 2023, Edwards Lifesciences launched its next-generation transcatheter aortic valve system with improved durability.

In 2022, Medtronic expanded its portfolio of transcatheter heart valve replacements to include new sizes, catering to a broader patient population.

In 2024, Abbott received FDA approval for its latest mitral valve repair device, targeting minimally invasive procedures.

Scope of Work – Global Structural Heart Devices Market

Key Market Developments:

2023: Edwards Lifesciences launched a novel transcatheter heart valve with improved long-term performance and durability.

2022: Boston Scientific announced a breakthrough in left atrial appendage closure (LAAC) technology.

2021: LivaNova PLC received regulatory approval for an innovative mitral valve repair system designed for minimally invasive applications.

Frequently Asked Questions (FAQs)

1. What is the current market size of the Global Structural Heart Devices Market?

The market was valued at USD 10.5 billion in 2023 and is projected to reach USD 19.2 billion by 2031.

2. What is the major growth driver of the Structural Heart Devices Market?

The market is primarily driven by the rising prevalence of structural heart diseases and increasing adoption of minimally invasive procedures.

3. Which region dominates the Structural Heart Devices Market?

North America holds the largest market share, with the United States leading due to high healthcare infrastructure and advanced cardiac procedures.

4. Which segment accounted for the largest market share in Structural Heart Devices Market?

The Heart Valve Devices segment, particularly Transcatheter Aortic Valve Replacement (TAVR), dominated the market in 2023.

5. Who are the key market players in the Structural Heart Devices Market?

Major players include Edwards Lifesciences, Medtronic, Abbott, Boston Scientific, LivaNova, and CryoLife, among others.

This report provides a comprehensive analysis of the Global Structural Heart Devices Market, covering industry trends, market drivers, competitive landscape, and growth opportunities.